Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ Sweden · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Apr 2026: SVT's Uppdrag granskning reported seven deaths where Cambio's Cosmic EHR was cited as a contributing factor in Swedish incident reports; Cambio said patient safety is its top priority and it had no information identifying Cosmic faults as a cause of death.
No data breaches, cyber incidents or regulator action involving Cambio found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Apr 2026: Swedish incident reports reviewed by SVT linked Cosmic to seven deaths and 646 deviations clearly attributed to the system since the 2024 Sussa rollout; Cambio says it has no information that Cosmic faults caused deaths.
Mar 2026: a Swedish appeal court ruled nine Sussa regions' amended Cosmic contract an unlawful direct award after Cambio's delayed delivery, fining each region SEK 10m (Cambio reportedly liable). Nov 2025: Region Stockholm and Gotland signed with Cambio.
No competitors linked yet.